Kardigan, Inc. (KARD)
21.92
+2.32
(+11.84%)
USD |
NASDAQ |
Sep 02, 16:00
21.88
-0.04
(-0.18%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.049B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 3.329 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0217 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ. |
| URL | http://www.kardigan.bio |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | N/A |
| Next Earnings Release | Nov. 09, 2026 (est.) |
| Last Earnings Release | Aug. 11, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ. |
| URL | http://www.kardigan.bio |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | N/A |
| Next Earnings Release | Nov. 09, 2026 (est.) |
| Last Earnings Release | Aug. 11, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |